02616 CSTONE PHARMA-B
- 1.370
- -0.050-3.52%
CSTONE PHARMA-B News
Changes in Hong Kong stocks | Cornerstone Pharmaceutical-B (02616) rose more than 12%, ROR1 ADC's latest research data will soon be revealed, ASCO's global space is expected to exceed 10 billion US dollars
The Zhitong Finance App learned that Cornerstone Pharmaceutical-B (02616) rose by more than 12%. As of press release, it had risen 12.73% to HK$1.24, with a turnover of HK$2.7634 million. According to the news, the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting will be held in Chicago from May 31 to June 4, US Eastern Time, in a combination of online and offline formats. The conference is one of the most important conferences in the field of global oncology. Among the 2024 ASCO ADC key clinical trials listed by Guosheng Securities, Cornerstone Pharmaceutical CS5001 is included in the treatment of patients with advanced solid tumors and lymphoma
Express News | CITIC Construction Investment: The national biotechnology and biomanfacture action plan is expected to be introduced in the near future, and the subsequent implementation of the policy is worth looking forward to
Changes in Hong Kong stocks | Cornerstone Pharmaceutical-B (02616) is now up nearly 4%. The company will release oncology drug research data at the ASCO annual meeting
Cornerstone Pharmaceuticals (02616) is now up nearly 4%. As of press release, it is up 3.7% to HK$1.12, with a turnover of HK$2.7921 million.
Agency: The synthetic biology sector showed a high increase in Q1 performance, and policy expectations accelerated valuation repair
Currently, the core competitiveness of biological manufacturing companies lies in product development and implementation capabilities. They are optimistic about targets with successful cases, leading positions, high-quality product reserves, and a boom in downstream demand.
Cstone Pharmaceuticals To Present Cancer Results at 2024 ASCO
Cstone Pharmaceuticals (HKG:2616) announced that the company will present Phase I results for its new cancer drug at the 2024 American Society of Clinical Oncology (ASCO) Meeting in a poster session,
Cornerstone Pharmaceutical-B (02616) will announce CS5001 (ROR1 ADC) Phase I study data at the 2024 American Society of Clinical Oncology Annual Meeting
Cornerstone Pharmaceutical-B (02616) issued an announcement. The company's R&D pipeline 2.0 blockbuster product CS5001 (RO...
Baili Tianheng and Shenzhou Cell turned losses into profits! Many biomedical companies on the Science and Technology Innovation Board ushered in a “good start” in Q1
In the first quarter of 2024, many parts of the country successively issued relevant policies to support the high-quality development of the biomedical industry or innovative pharmaceutical devices to continuously optimize the biomedical innovation environment.
Non-Executive Director Increases Shareholding in CStone Pharma; Shares Surge 25%
Kenneth Walton Hitchner, a non-executive director at CStone Pharma (HKG:2616), increased his shareholding in the company by purchasing 2,219,500 shares in the open market from April 9 to April 19 at a
Changes in Hong Kong stocks | Cornerstone Pharmaceutical-B (02616) rose more than 26%, leading the innovative drug concept, ASCO catalyzes market conditions, institutions are optimistic about policy+health insurance marginal improvement
Zhitong Finance App learned that innovative drug concept stocks showed strong performance. As of press release, Cornerstone Pharmaceutical-B (02616) rose 26.14% to HK$1.11; Cansino Biotech (06185) rose 16.91% to HK$20.95; Gacos-B (01167) rose 14.2% to HK$1.93; Nuocheng Jianhua (09969) rose 12.31% to HK$5.2; Rongchang Biotech (09995) rose 10.2% to HK$30.8. According to the news, the research title of the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting was on April 25
Changes in Hong Kong stocks 丨 Biotech stocks continue to strengthen, the cornerstone pharmaceutical industry rises nearly 23%
Glonghui, May 2 | Cornerstone Pharmaceuticals rose nearly 23%, Cansino Biotech rose nearly 14%, Lepu Biotech rose more than 10%, and Pharmaceutical Kangde rose nearly 8.5%.
Cornerstone Pharmaceutical-B (02616.HK): Non-executive director Kenneth Walton Hitchner III increased shareholding by 2,219,500 shares
Gelonghui May 2 | Cornerstone Pharmaceutical-B (02616.HK) announced that Mr. Kenneth Walton Hitchner III (“Mr. Hitchner”), a non-executive director of the company, increased his shareholding in the company. The company was informed by Mr. Hitchner that it used its own capital to purchase a total of 2,219,500 shares on the open market between April 9 and April 19, 2024, at an average purchase price of approximately HK$0.86. After the bank purchased the shares, Mr. Hitchner held a total of 2,613,500 shares, which is equivalent to
Cstone Pharmaceuticals' CEO Boosts Stakeholding
Cstone Pharmaceuticals' (HKG:2616) CEO Jianxin Yang bought around an additional 3.3 million shares on the market during the six months ended today, Monday, a same-day filing on the Hong Kong bourse sa
Cornerstone Pharmaceutical-B (02616.HK): CEO and Executive Director Yang Jianxin purchased 3.345 million additional shares of the company, with a total purchase of 7,529,500 shares
Gelonghui, April 29 | Cornerstone Pharmaceutical-B (02616.HK) announced that the company was informed by Yang Jianxin, CEO, R&D President and Executive Director, that it purchased a total of 3.345 million shares on the open market with its own capital about six months before the announcement date. Since Yang Jianxin became CEO in August 2022, he has purchased a total of 7,529,500 shares. The purchase price range is HKD0.82 to HKD4.60. After the share purchase, Yang Jianxin held a total of about 4.97% of the company's total issued share capital at the date of the announcement.
Cornerstone Pharmaceutical-B (02616.HK) received Kenneth Walton Hitchner III an increase of 319,500 common shares worth approximately HK$278,700
On April 25, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on April 25, Kenneth Walton Hitchner III increased its share holdings of $Cornerstone Pharmaceutical-B (02616.HK) by $319.5 million at an average price of HK$0.8722 per share, worth approximately HK$278,700. After the increase in holdings, Kenneth Walton Hitchner III's latest shareholding was 1.33 million shares, and the good position ratio increased from 0.08% to 0.10%. Additional Information: Box 28: Such d
[Stock Exchange Amendment] Cornerstone Pharmaceutical-B (02616.HK) received 90,500 additional shares of common stock from Kenneth Walton Hitchner III, worth approximately HK$79,000
On April 25, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on April 25, Kenneth Walton Hitchner III increased its share holdings of $Cornerstone Pharmaceutical-B (02616.HK) by $90,500 at an average price of HK$0.8729 per share, worth approximately HK$79,000. After the increase in holdings, Kenneth Walton Hitchner III's latest shareholding was 737,000 shares, and the good position ratio increased from 0.05% to 0.06%. Additional Information: Box 24: Number o
Cornerstone Pharmaceutical-B (02616.HK) received 264,000 additional shares worth HK$221,400 from Kenneth Walton Hitchner III
On April 25, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on April 25, Kenneth Walton Hitchner III increased its share holdings of $Cornerstone Pharmaceutical-B (02616.HK) by $264,000 at an average price of HK$0.8387 per share on April 16, worth approximately HK$221,400. After the increase in holdings, Kenneth Walton Hitchner III's latest shareholding was 1.594 million shares, and the good position ratio increased from 0.10% to 0.12%. Additional Information: Box 28: Such
Cornerstone Pharmaceutical-B (02616.HK) gains 160,000 shares of common stock worth approximately HK$137,800 from Kenneth Walton Hitchner III
On April 25, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on April 25, Kenneth Walton Hitchner III increased its share holdings of $Cornerstone Pharmaceutical-B (02616.HK) by $160,000 at an average price of HK$0.861 per share, worth approximately HK$137,800. After the increase in holdings, Kenneth Walton Hitchner III's latest shareholding was 1.754 million shares, and the good position ratio increased from 0.12% to 0.14%. Additional Information: Box 28: Such der
[Stock Exchange Amendment] Cornerstone Pharmaceutical-B (02616.HK) received Kenneth Walton Hitchner III an increase of 121,500 common shares worth approximately HK$105,600
On April 25, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on April 25, Kenneth Walton Hitchner III increased its share holdings of $Cornerstone Pharmaceutical-B (02616.HK) by $121,500 at an average price of HK$0.869 per share, worth approximately HK$105,600. After the increase in holdings, Kenneth Walton Hitchner III's latest shareholding was 858,500 shares, and the good position ratio increased from 0.06% to 0.07%. Additional Information: Box 24: Numbe
Cornerstone Pharmaceutical-B (02616.HK) was increased by 50,000 shares of common stock by Jianxin Yang, worth approximately HK$41,500
On April 25, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on April 25, Jianxin Yang increased its share holdings of $Cornerstone Pharmaceutical-B (02616.HK) by 50,000 shares at an average price of HK$0.8305 per share, worth approximately HK$41,500 on April 22. After the increase in holdings, Jianxin Yang's latest shareholding was 63.66,800 shares, and the good position ratio increased from 4.95% to 4.96%. Additional Information: Box 28: Such Shares Requested the Restricted
[Stock Exchange Amendment] Cornerstone Pharmaceutical-B (02616.HK) received 152,000 additional shares of common stock from Kenneth Walton Hitchner III, worth approximately HK$133,200
On April 25, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on April 25, Kenneth Walton Hitchner III increased its share holdings of $Cornerstone Pharmaceutical-B (02616.HK) $152,000 on April 12 at an average price of HK$0.8763 per share, worth about HK$133,200. After the increase in holdings, Kenneth Walton Hitchner III's latest shareholding was 1,010,500 shares, and the good position ratio increased from 0.07% to 0.08%. Additional Information: Box 24: Numb
Analysis
Price Target
No Data
